Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell

Lyra Therapeutics, Inc.

Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.
Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.
Company has requested hearing to appeal delisting; stay in effect pending panel decision.
CEO and CFO now consultants; no ongoing operations after workforce reduction.

item 3.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-041191
form_type: 8-K
ticker: LYRA
cik: 0001327273
company_name: Lyra Therapeutics, Inc.
filed_at: 2026-02-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:34.819951+00:00
generated_at: 2026-05-16T04:02:36.002486+00:00
sec_items: ["3.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.95
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-041191
json_url: https://secwatch.observer/filing/0001193125-26-041191.json
markdown_url: https://secwatch.observer/filing/0001193125-26-041191.md
text_url: https://secwatch.observer/filing/0001193125-26-041191.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/0001193125-26-041191-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/d157841d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-041191

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.